A total of 110 patients (71 adults and 39 children) who received allogeneic haematopoietic stem cell transplantation from HLA-matched sibling donors were studied for the incidence of acute graft-versus-host disease (aGvHD) in relation to IFN-gamma gene microsatellite polymorphism. A strong tendency was observed towards the lower incidence of grades II-IV aGvHD in patients having an IFN-gamma 2/2 genotype as compared to the recipients with other IFN-gamma genotypes (0.12 vs 0.33, P ¼ 0.06). This relationship was independent of the intensity of conditioning regimen and diagnosis. IFN-gamma polymorphic features, together with other clinical and biological factors (patient's age, donor-recipient gender, diagnosis, conditioning regimen, transplant material and GvHD prophylaxis), were subjected to multivariate analysis for aGvHD manifestation in order to exclude indirect association of the IFN-gamma 2/2 genotype. In multivariate analysis, myeloablative therapy (OR ¼ 11.462, P ¼ 0.013), recipient age (OR ¼ 4.896, P ¼ 0.009) and lack of IFN-gamma 2/2 genotype (OR ¼ 4.311, P ¼ 0.048) were found to significantly contribute to the development of grade II-IV aGvHD, while type of GvHD prophylaxis showed less-strong influence (OR ¼ 2.963, P ¼ 0.066). Thus, it appeared that the IFN-gamma 2/2 genotype constituted an independent and protective factor associated with a decreased risk of grade II-IV aGvHD. However, this genotype was not found to be associated with the risk of cGvHD or survival.
microsatellite; aGvHD; HSCT Allogeneic haematopoietic stem cell transplantation (HSCT) is an effective therapeutic approach for the treatment of haematological malignancies and nonmalignant haematopoietic disorders. Graft-versus-host disease (GvHD) is one of the major complications occurring in the recipients of allogeneic HSCT. IFN-gamma is a cytokine strongly involved in perpetuation of this disease and plays the central role in donor and host cell expansion. 1 Single-nucleotide polymorphism (SNP) and microsatellite polymorphism were detected in the first intron of the IFN-gamma gene. SNP is characterised by an A/T substitution at position þ 874, 2 while STR polymorphism shows the different number (11) (12) (13) (14) (15) of CA repeats. 3 Pravica et al 2 documented a correlation of SNP and STR in the first intron of the human IFN-gamma gene. They showed that 12 CA repeats (corresponding to allele 2) were associated with the presence of T at position þ 874, whereas 13, 14 and 15 CA repeats (corresponding to alleles 3, 4 and 5, respectively) were linked to A in this polymorphic site.
Recent studies have shown that the generation potential of this cytokine is influenced by the polymorphism of the IFN-gamma gene. Using a number of different assays, several groups investigated the effect of STR and SNP ( þ 874) polymorphisms on IFN-gamma production (reviewed by Warle et al 4 
and Vanderbroeck and Goris 5
). It was generally found that individuals homozygous for STR allele 2 (or having T at polymorphic position þ 874), in contrast to those carrying allele 3 (or þ 874 A), had a greater IFN-gamma secretion by peripheral blood mononuclear cells (PBMC) upon different mitogen stimulations. 2, 3 There are conflicting data regarding the IFN-gamma gene polymorphisms and a risk of aGvHD. Socie et al failed to show any association between the presence of different IFN-gamma genotypes and aGvHD incidence. 6 However, more recently, Cavet et al documented that IFNgamma 3/3 homozygous patients more frequently developed severe (III-IV grade) aGvHD. 7 The results of our preliminary study favoured rather the latter association between IFN-gamma gene polymorphism and aGvHD. 8 Therefore, to re-evaluate our primary observations, we intensified our present work by extending the numbers of patients and controls, and by the use of more complex statistical analysis. In addition, we also verified the previously reported association between the A/T þ 874 alleles and the number of CA repeats. 2 As a result, we show that the 2/2 IFN-gamma genotype is protective for aGvHD. Interestingly, in one of 110 individuals investigated, the patient possessing 2/3 microsatellite genotype had TT at þ 874 SNP position, but not AT, as might be expected in the light of previous reports.
2,3
Patients, materials and methods
Characteristic of the HSCT patient group
In total, 71 adults and 39 children, who received HLAmatched sibling haematopoietic stem cell transplantation between 1992 and 2001 in our BMT Unit for haematological malignancies (n ¼ 84), anaemias (n ¼ 21) and immunodeficiencies (n ¼ 5), were studied for the incidence of aGvHD in relation to IFN-gamma gene microsatellite polymorphism (for details, see Table 1 ). All the patients and theirs donors were of Polish origin. The study was approved by the local ethics committee.
HLA typing had been performed either serologically or by low-resolution molecular typing for HLA-A and -B and at high-resolution DNA typing for DRB1.
The patients in the group differed with respect to the conditioning regimen (myeloablative or reduced-intensity conditioning), source of stem cells (marrow or peripheral blood stem cells), donor-recipient gender relation (sex matched or mismatched) and GvHD prophylaxis (cyclosporine (CsA) or CsA with methotrexate (MTX) or CsA with mycophenolate mofetil (MMF)).
Acute GvHD was graded according to the consensus conference on aGvHD grading. 9 Among the 110 patients, 64 did not develop aGvHD, whereas 17, 19, 5 and 5 had I, II, III and IV grade aGvHD, respectively (Table 1) . A total of 24 patients presented with cGvHD. In all, 37 patients died after transplantation (among them 22 before þ 100 day post transplant).
DNA extraction
DNA was extracted from peripheral blood using silica membranes (QiAmp Blood kit, Qiagen, Hilden, Germany) following the recommendation of the manufacturer.
IFN-gamma intron 1 (CA) n microsatellite genotype
The 122-128 bp fragment of the first intron of the IFNgamma gene, containing the (CA) n microsatellite region, was amplified using two primers: forward 5 0 -GCT GTC ATA ATA ATA TTC AGA C-3 0 and reverse labelled with TAMRA 5 0 -CGA GCT TTA AAA GAT AGT TCC-3 0 , according to the method described by Awad et al. In all, 1 ml of PCR products and 0.5 ml of internal size standard (Genescan ROX 500, ABI, Warrington, UK) were mixed with 6 ml of loading buffer (formamide, bromophenol blue 5:1). After denaturation at 951C for 5 min, all samples were analysed on 6% polyacrylamide gel with 7 M urea (Gibco, Paisley, Scotland, UK) on the ABI 377 automated DNA sequencer (Applied Biosystem, USA). Electrophoresis was carried out for 4 h with 3000 V, at 511C. The analysis of results was performed using the genescan 2.1 software (Applied Biosystems). 
Sequence analysis
DNA samples taken from three homozygous individuals (two with genotype 2/2 and one with 3/3) were sequenced to verify the relationship between the size of PCR products and the number of CA repeats. For sequencing, the same primers as employed for microsatellite genotyping, spanning the CA polymorphic region, were used. The analysis was performed by using the 2.1 Sequencing Kit Big Dye Terminators (Applied Biosystem, CA, USA). It appeared that homozygous individuals with genotype 2/2 had 12 CA repeats and homozygous with genotype 3/3 had 13 CA repeats.
IFN-gamma ( þ 874 T/A) SNP polymorphism
The IFN-gamma ( þ 874 T/A) SNP was determined by allele-specific PCR, using primers amplifying the region ( þ 812-þ 932) of the first intron of the IFN-gamma gene, provided with the Cytokine Genotyping Tray (One Lambda, Inc., Canoga Park, CA, USA). Allele-specific PCRs were carried out as recommended by the manufacturer. In brief, two PCR reactions were performed for each DNA sample. Each reaction contained four primers: two control primers, one primer common for both specific amplifications and one specific for a particular IFN-gamma allele. PCR cycling conditions were as follows: 961C for 130 s, 631C for 60 s, followed by nine cycles of 961C for 10 s, 631C for 60 s, and 20 cycles of 961C for 10 s, 591C for 50 s and 721C for 30 s. PCR products were resolved by 2% agarose gel electrophoresis and visualised by ethidium bromide staining.
Statistical analysis
Distribution of IFN-gamma genotypes in patients having and lacking aGvHD (II-IV grades) was compared by the Fisher exact test. The Statistical Package for Social Scientists (SPSS, SYSTAT 10) was used for multivariate complete logistic regression analysis.
Results

IFN-gamma allele frequencies
Five alleles were documented at the microsatellite locus within the first intron of the IFN gamma gene. 3 Four of them were identified in our patients (n ¼ 110). Table 2 presents the distributions of the IFN-gamma microsatellite alleles and genotypes in our recipients. The most common alleles were alleles 2 and 3, corresponding to 12 and 13 CA repeats, respectively (48 and 46%). They appeared more frequent than alleles 4 and 5. Homozygous 2/2 and 3/3 cases were less frequent than 2/3 heterozygotes.
Correlation between number of CA repeats and SNP
In our analysis, the association between the number of STR-PCR-assessed CA repeats and the presence of T or A in the position þ 874 analysed using PCR-SSP was seen in 109 out of 110 individuals studied. We observed that 24 homozygous patients with 12 CA repeats were also homozygous for the allele T in the position þ 874. The presence of 13, 14 or 15 CA repeats was connected with A in the position þ 874.
However, in one patient, microsatellite polymorphism did not correlate with the presence of SNP T alleles. In the latter case, 12 and 13 CA repeats were detected (genotype 2/3), but this patient was TT homozygote. To verify this unexpected observation being at variance with previous reports, 2,3 the family study, involving both parents, one sister and one brother, was performed. Correlation between the microsatellite and SNP alleles was seen in the mother (TA and 12 and 13 CA repeats), sister and brother (both, AA and 13 CA repeats). However, in the father, typed as a TA heterozygote, only 13 CA repeats were detected and the patient (probant) inherited the T allele associated with 13 CA repeats (Figure 1) .
For the further analyses, we decided to use the microsatellite polymorphic pattern of this patient.
Factors affecting the development of aGvHD
Patients having an IFN-gamma 2/2 genotype tended less frequently to develop II-IV grades aGvHD as compared to the recipients with other IFN-gamma genotypes (2/3, 3/3, 3/4 and 3/5). Grade II-IV aGvHD was seen in 26 out of 86 patients lacking 2/2 homozygous genotype, and only in 
Alleles 2-5 characterise with 12-15 CA repeats within the first intron of IFN-gamma encoding the gene, respectively. The development of grades II-IV aGvHD was more frequent among patients with haematological malignancies than those with anaemias or immunodeficiencies (26/84 vs 3/26, P ¼ 0.039). However, the impact of IFN-gamma 2/2 homozygosity was also observed in both groups of patients. Among patients with haematological malignancies, only three out of 19 individuals having IFN-gamma 2/2 developed grades II-IV aGvHD as compared to 23 out of 65 patients carrying the other IFN-gamma genotypes (0.16 vs 0.35, P ¼ 0.086). There were no IFN-gamma 2/2 homozygous patients with anaemia, who developed aGvHD (grades II-IV).
More intensive conditioning regimens strongly influenced the manifestation of aGvHD. Among 62 patients receiving a myeloablative conditioning regimen, 25 developed grades II-IV aGvHD, while among 48 patients treated with RIC only four had grades II-IV aGvHD (0.40 vs 0.08, Po0.001). Similar relationships were observed for more severe grades III-IV aGvHD (0.15 vs 0.02, P ¼ 0.023). The lower incidence of aGvHD in patients having 2/2 genotypes was observed independently of the intensity of conditioning regimen. Three out of 14 patients on myeloablative treatment with IFN-gamma 2/2 and 23 out of 48 patients receiving the same therapy but lacking IFN-2/2 genotype developed aGvHD (0.21 vs 0.48, P ¼ 0.07). Among 18 patients treated with aggressive myeloablative conditioning regimen, aGvHD was seen only in one patient with IFN-gamma 2/2 and 11/15 patients having the other IFN-gamma genotypes (0.33 vs 0.73, ns).
Grades II-IV aGvHD were also more frequent among bone marrow transplant recipients as compared to patients transplanted with PBPC; however, this relationship was not statistically significant (0.33 vs 0.19, P ¼ 0.066).
In addition, patients receiving GvHD prophylaxis with CsA and MTX or MMF tended to develop aGvHD grades II-IV and III-IV more frequently than those receiving CsA alone (P ¼ 0.10 in both cases). In the group of patients who received CsA with MTX or MMF, the presence of IFN-gamma 2/2 genotype was associated with the lower incidence of grades II-IV aGvHD (0.08 vs 0.38, P ¼ 0.033). This difference was not seen in patients receiving CsA alone; this might be due to the low number of IFN-gamma 2/2-positive patients in this group.
Associations between different risk factors of aGvHD may be indirect as, for example, PBPC-receiving patients more frequently received RIC than myeloablative conditioning regimen (0.68 vs 0.32). Similarly, haematological malignancy patients were treated with more aggressive conditioning regimens than those with anaemias and immunodeficiencies (0.71 vs 0.08). A constant feature found in different groups of patients (categorised with respect to diagnosis and intensity of conditioning regimen) was that the IFN-gamma 2/2 genotype had a protective role. To elucidate this observation and to objectify associations found, a multivariate analysis was performed.
Multivariate analysis of risk factors associated with aGvHD
IFN-gamma polymorphic features (associating with the presence of IFN-gamma 2 allele), together with the other factors, known to contribute to the development of aGvHD, were subjected to multivariate logistic regression analysis. The following factors were included: recipient age, donor-recipient gender relation, conditioning regimen, diagnosis, source of transplant material, GvHD prophylaxis and IFN-gamma genotypes. The results are given in Table 3 . It appeared that three variables were significantly associated with the risk of aGvHD. Myeloablative therapy (OR ¼ 11.462, P ¼ 0.013), recipient age (OR ¼ 4.896, P ¼ 0.009) and lack of IFN-gamma 2/2 genotype (OR ¼ 4.311, P ¼ 0.048) significantly contributed to the development of grade II-IV aGvHD. Type of GvHD prophylaxis was found to be a less significant factor influencing the risk of aGvHD manifestation (OR ¼ 2.963, P ¼ 0.066). Thus, it appeared that the IFNgamma 2/2 genotype when confronted with other risk factors showed an independent influence on aGvHD manifestation. Myeloablative conditioning regimen, recipient age and lack of IFN-gamma 2/2 homozygous genotype constitute the risk factors of grade II-IV aGvHD. Significant associations are given in bold.
Distribution of IFN-gamma 2/2 genotype in relation to cGvHD and survival
Chronic GvHD was observed more frequently among patients with haematological malignancies (22/84 vs 2/26, P ¼ 0.036), those who had previously developed grades II-IV aGvHD (10/29 vs 14/81, P ¼ 0.051) and received a more intensive conditioning regimen (17/63 vs 7/48, P ¼ 0.082, for patients treated with myeloablative and RIC therapy, respectively). However, IFN-gamma 2/2 genotype, although found to associate with aGvHD, did not appear to prevail in patients with cGvHD. Among 24 patients who developed cGvHD, four had an IFN-gamma 2/2 genotype, while 26 out of 86 patients lacking cGvHD were homozygous for IFN-gamma 2/2 (0.17 vs 0.30, ns). Also, no relationship was seen between the source of transplant material and cGvHD.
Fatal cases were more frequent among patients suffering from haematological malignancies (33/84 vs 4/26, P ¼ 0.019), those who received myeloablative therapy (27/ 62 vs 10/48, P ¼ 0.010) or presented with aGvHD (II-IV) (14/29 vs 23/81, P ¼ 0.045). Chronic GvHD was not found to affect the patients' survival. No association between the IFN-gamma 2/2 genotype and survival was observed. We also looked to see whether there was a relationship between the time post transplant and the fatal outcome. However, no difference occurred in the distribution of IFN-gamma 2/2 among patients who died before or at 100 days after transplantation.
Discussion
Acute GvHD constitutes the major complication after allogeneic HSCT. In patients after allogeneic HSCT, the toxicity of chemotherapy, microbial complications and alloreactivity exerted by transplanted lymphocytes are associated with generation of cytokines. IFN-gamma, produced by both CD4 þ cells and natural killer (NK) cells, 11 is one of the key cytokines involved in the cytokine storm associated with aGvHD manifestation and perpetuation. This cytokine, together with TNFa, is implicated as a mediator of aGvHD in a skin explant model. 12, 13 In human clinical HSCT, a large number of T-cell clones produce IFN-gamma, whereas levels of IFN-gamma increase both before and during aGvHD. Also, in homogenates of biopsy specimens taken from advanced aGvHD skin lesions, the presence of mRNA for IFN-gamma and IP-10 (reflecting the biological impact of IFN-gamma), as well as for TNFa, was found. 14, 15 The magnitude of cytokine production depends on the severity of the latter situations and the ability of the individuals to generate different cytokines. Generation potential of a given cytokine may be associated with polymorphic features of the cytokine-encoding gene. This has been shown for TNF-alpha, 16 IL-6, 17 IL-10 and also for IFN-gamma. 3 The present work was undertaken to analyse the relationship between the polymorphism within the first intron of the IFN-gamma gene in the recipients of allogeneic HSCT and the aGvHD manifestation. SNP ( þ 874 T/A) alleles and the number of CA repeats were determined.
Previous reports documented that SNP associates with STR within the first intron of the IFN-gamma gene. 2, 3 In the present work, we noticed a previously unpublished exception, in that in one out of 110 cases SNP allele 3 (corresponding to 13 CA repeats) was associated with T at position ( þ 874), instead of A. This unexpected relationship was confirmed by a family study and might be caused by mutation changes.
The novel feature of our work was the finding that the IFN-gamma 2/2 genotype is associated with a lower susceptibility to aGvHD. This is a novel observation, which however mirrors the previously published data on the positive correlation between IFN-gamma 3/3 homozygosity and more frequent development of severe (III-IV grade) aGvHD. 7 The latter was also seen in our group of patients, but not at the statistically significant level (0.30 vs 0.19, ns for IFN-gamma 3/3 homozygous patients having and lacking aGvHD grades III-IV, respectively). The positive association of IFN-gamma 3/3 homozygosity with aGvHD reported by Cavet et al 7 and the negative correlation between IFN-gamma 2/2 alleles with aGvHD observed in our work mutually confirm the results of both these studies. Both studies, of Cavet et al 7 and our present one, strongly suggest that IFN-gamma allelic STR polymorphism constitutes a risk factor shaping the alloreactivity after allogeneic HSCT. These data imply that IFN-gamma 1 intron polymorphism influences the susceptibility for aGvHD manifestation and that a higher risk of this complication is associated with IFN-gamma 3/3 homozygosity, while IFNgamma 2/2 genotype plays a protective role.
The rationale behind this finding cannot be discussed on the basis of the present study. Importantly, IFN-gamma 2/2 genotype making the patients less susceptible to aGvHD was postulated to be associated with a higher IFN-gamma production. 2, 3 If this observation is valid for the patients after HSCT, it might suggest that patients more prone to IFN-gamma generation provide a tissue environment preventing aGvHD lesions. Interestingly, we found that IFN-gamma 2/2-positive patients less frequently suffer from EBV reactivation. 18 Therefore, one can assume that patients carrying the IFN-gamma 2/2 genotype are characterised by better surveillance of viral reactivation. Viruses, especially those from the herpes family, play an important role in aggravating aGvHD. 1 Thus, IFN-gamma polymorphic features may contribute to the initiation and perpetuation of aGvHD by controlling viral surveillance. In favour of this assumption is also our more recent observation that sarcoidosis patients carrying IFN-gamma 3/3 genotype are more prone to Lo¨fgren's syndrome, characterised by erythema nodosum, arthritis and fever, and associated with decreased IFN-gamma production. 19 For the last couple of years, a number of publications have appeared suggesting the associations of the polymorphic features of cytokine genes and the risk of aGvHD. [6] [7] [8] 20, 21 Our present study contributes to the previous findings. It becomes apparent that IFN-gamma 2/2 genotype constitutes an independent and protective factor associated with a decreased risk of grade II-IV aGvHD.
